Chuzhou

Researchers are establishing a standardized clinical information database for liver cancer patients through a collaborative effort led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China (USTC). This database aims to support high-quality real-world clinical studies and research on hepatocellular carcinoma and related liver cancers. Participants may receive routine treatments such as surgical operations including resection, ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). They might also be treated with various anti-tumor drugs including immunologic, targeted, and chemotherapy medications. Treatments and clinical data are collected to enrich the database for future research. During the study, participants will provide blood samples and postoperative pathology residual samples and will be followed over time to monitor their health and treatment outcomes. The primary outcome measured is overall survival over 10 years. Participants must be willing to comply with follow-up visits and provide informed consent, ensuring comprehensive data collection for long-term analysis.

Researchers are evaluating the safety and effectiveness of giving tirofiban early to patients who have received tenecteplase for acute ischemic stroke. This phase 3 study addresses the problem of reocclusion that happens in 14-34% of patients after thrombolysis, likely due to platelet activation. The goal is to see if adding tirofiban soon after tenecteplase can reduce this risk and improve patient outcomes. Participants will be randomly assigned to receive either a continuous intravenous infusion of tirofiban or a placebo. The infusion starts at 0.3 micrograms per kilogram per minute for 30 minutes, followed by 0.075 micrograms per kilogram per minute for 47.5 hours, beginning within 4 to 24 hours after tenecteplase treatment. Aspirin and/or clopidogrel placebos are given orally 24 hours after tenecteplase, with actual antiplatelet therapy starting at 44 hours and continuing until 90 days after randomization. During the study, participants are monitored for neurological function changes and safety. The main outcome measured is excellent functional recovery 90 days after randomization. The study includes neurological assessments, imaging tests, and laboratory evaluations. Participants are followed for 90 days to observe treatment effects and any adverse events.

Researchers are studying patients with colorectal cancer that has spread to the liver and other organs to understand if local radical treatment of liver metastases combined with systemic therapy can improve survival and affect prognosis. This study also aims to identify risk factors related to patient outcomes and assess quality of life and treatment safety. It is a prospective, multicenter, non-randomized controlled study focusing on patients with resectable liver and controllable extrahepatic metastases. Participants are assigned to one of two groups based on their willingness. Group I will receive radical local treatment of liver metastases, such as hepatectomy or ablation, combined with systemic therapies including chemotherapy, targeted drugs, or immunotherapy. Group II will receive systemic therapy alone or systemic therapy combined with local interventions like transcatheter arterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC). The treatments and follow-up evaluations occur over a period of up to two years, with follow-up visits every three months. During the study, participants will undergo regular assessments including imaging to confirm metastases, laboratory tests to monitor health status, and questionnaires to evaluate quality of life. Researchers will track overall survival from study inclusion up to two years or until death. Safety and treatment effectiveness will be monitored throughout, along with identifying factors that may influence patient prognosis. The study includes patients aged 18 to 80 years with good performance status and controlled extrahepatic disease.

Researchers are evaluating the effectiveness and safety of TQB2102 for injection, a HER2 dual-antibody-drug conjugate, in patients with HER2 negative recurrent or metastatic breast cancer. This Phase II clinical trial focuses on individuals whose cancer has returned or spread and who are not suitable for surgery or radiation aimed at a cure. Participants must have measurable tumors, adequate organ function, and have experienced disease progression or intolerance to previous treatments, including chemotherapy or targeted therapies. Participants will receive TQB2102 for injection as the study treatment. The trial monitors the response to this drug over a period of up to 24 months. Female participants of childbearing age must agree to use contraception during the study and for six months afterward, and males must also agree to avoid pregnancy during this time. The study excludes individuals with recent surgeries, uncontrolled illnesses, certain lung diseases, recent other cancer treatments, or allergies to the investigational drug. Throughout the study, participants will undergo regular evaluations to assess tumor response according to standardized criteria. The primary outcome measured is the objective response rate, which will be assessed for up to two years from the start of the study. Safety monitoring and adherence to treatment protocols will be conducted continuously to ensure participant well-being and accurate study results.

Researchers are evaluating gastrointestinal bleeding in patients with acute coronary syndrome (ACS) who have undergone Percutaneous Coronary Intervention (PCI) and require long-term dual antiplatelet therapy (DAPT). Helicobacter pylori (Hp) infection is a common risk factor for gastrointestinal bleeding in these patients. This open-label, randomized, controlled phase 4 trial compares the effects of a novel dual eradication therapy using Vonoprazan combined with amoxicillin against routine proton pump inhibitor (PPI) treatment with pantoprazole on bleeding events in ACS patients with Hp infection and coronary stents. The study plans to enroll 2600 patients, randomly assigning 1300 to each group. The test group will receive a 14-day course of Vonoprazan 20 mg twice daily plus amoxicillin 1 g three times daily for Hp eradication, followed by 6 months of monitoring. The control group will receive pantoprazole 40 mg daily for 6 months. All patients will continue their DAPT regimen, which includes aspirin plus either clopidogrel or ticagrelor, as determined by their doctor. Hp infection will be confirmed using urea breath tests and antibody detection, and eradication success will be retested about 12 weeks after treatment. Participants will be monitored for gastrointestinal bleeding and adverse reactions over 6 months. Follow-up visits will include breath tests for Hp, safety visits for adverse event reporting, and documentation of treatment adherence. The primary outcome is the incidence of gastrointestinal bleeding within 6 months after PCI. This trial aims to provide evidence on whether Vonoprazan-based dual eradication therapy is a safe and effective alternative to routine PPI treatment in reducing bleeding risk in this high-risk patient group.